Table IV.
Gene | Promoter | 5′-UTR | Exons (ORF) | 3′-UTR | Introns |
---|---|---|---|---|---|
Chga | −1694 In/Del A-1616T-753 In/Del C-177T C-59T | None | +6361 In/Del+8093In/Del | G+11177T | T+413C, C+885G, A+1113G, A+1196T, G+3033T, C+3168T, +3386 In/Del, C+3863T, T+3961C, C +6587T, A+8388G, G +10882A (3775/9465 bp; 39.9%) |
Comt | None | None | None | None | None (297/3470 bp; 8.6%) |
Ednrb | None | None | None | None | None (958/4589 bp; 20.9%) |
Etfdh | None | None | None | None | None (1953/19,833 bp, 9.8%) |
Npy | −1025 In/Del | None | None | None | None (765/6639 bp, 11.5%) |
UTR, untranslated region; ORF, open reading frame; Chga, chromogranin A; Comt, catechol-O-methyltransferase; Ednrb, endothelin receptor type B; Etfdh, electron transferring flavoprotein dehydrogenase; Npy, neuropeptide Y. Polymorphisms discovered in the promoter, 5′-UTR, exons (ORF), 3′-UTR, and introns of Chga, Comt, Ednrb, Etfdh and Npy are listed. Multiple polymorphisms were discovered throughout the Chga locus. No polymorphisms were detected in Comt, Ednrb and Etfdh. One polymorphism was discovered in the Npy locus. Introns were not specifically targeted for polymorphism discovery and the sequencing coverage is indicated in parentheses in the final column (bp sequenced/total bp in all introns; % coverage). Polymorphism nomenclature: [Wistar-Kyoto (WKY) allele] [base pair position] [spontaneously hypertensive rat (SHR) allele]; promoter polymorphism position is indicated in terms of base pairs upstream of the transcriptional start site (5′-cap site); exonic (UTR and ORF) and intronic polymorphism position is indicated in terms of base pairs downstream from the transcriptional start site (5′-cap site); In/Del, insertion/deletion; A, adenine, G, guanine; C, cytosine; T, thymine.